SCHEMBL4861231

SCHEMBL4861231

CNC(=O)[C@@H](Cc1c[nH]c2ccccc12)NP(=O)(O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 11/20 0.60
MMP8 P22894 10/20 0.60
MMP1 P03956 6/20 0.60
MMP3 P08254 5/20 0.60
MMP2 P08253 12/20 0.58
ACE P12821 2/20 0.58
MMP14 P50281 2/20 0.56
ADAM10 O14672 1/20 0.56
ADAM12 O43184 1/20 0.56
ADAMTS4 O75173 1/20 0.56
MMP7 P09237 1/20 0.56
MMP12 P39900 1/20 0.56
MMP13 P45452 1/20 0.56
MMP15 P51511 1/20 0.56
MMP16 P51512 1/20 0.56
ADAM17 P78536 1/20 0.56
ADAM9 Q13443 1/20 0.56
MMP26 Q9NRE1 1/20 0.56
MMP17 Q9ULZ9 1/20 0.56
ADAMTS5 Q9UNA0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15902638 1.00 MMP9 (0.60) MMP9MMP8MMP1MMP3MMP2
SCHEMBL7103470 0.86 ACE (0.65) MMP9MMP2ACEALOX15ITGB2
SCHEMBL7103473 0.86 ACE (0.65) MMP9MMP2ACEALOX15ITGB2
SCHEMBL16182036 0.86 MMP9 (0.66) MMP9MMP8MMP1MMP3MMP2
SCHEMBL6577399 0.86 MMP9 (0.66) MMP9MMP8MMP1MMP3MMP2
Hydrochloric Acid SCHEMBL6044254 0.85 MMP9 (0.65) MMP9MMP8MMP1MMP3MMP2
Hydrochloric Acid SCHEMBL6044250 0.85 MMP9 (0.65) MMP9MMP8MMP1MMP3MMP2
SCHEMBL25139559 0.82 MMP9 (0.76) MMP9MMP8MMP1MMP3MMP2
SCHEMBL3787557 0.82 MMP9 (0.72) MMP9MMP8MMP1MMP3MMP2
SCHEMBL24814079 0.82 MMP9 (0.69) MMP9MMP8MMP1MMP3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2008523082-A 2008-07-03 JP claimed
EP-1827460-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2007-09-05 EP claimed
WO-2006063149-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2006-06-15 WO claimed
US-20200095273-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-03-26 US disclosed
US-20180258131-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-09-13 US disclosed
US-20160159845-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA 2016-06-09 US disclosed
US-20150025220-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-01-22 US disclosed
US-8815830-B2 Nucleosides with antiviral and anticancer activity REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-08-26 US disclosed
US-20140213543-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-07-31 US disclosed
EP-1827460-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2007-09-05 EP disclosed
WO-2006063149-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200095273-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY SLC29A1, TYMP, NTPCR MMP9 1212/4885MMP8 2487/4885MMP1 2825/4885
US-20160159845-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY TYMP, SLC29A1, NTPCR MMP9 1527/4885MMP8 2924/4885MMP1 3024/4885
US-20180258131-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY TYMP, SLC29A1, NTPCR MMP9 1527/4885MMP8 2924/4885MMP1 3024/4885
US-20150025220-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY TYMP, RNASE1, SLC29A1 MMP9 1235/4885MMP8 2738/4885MMP1 2280/4885
US-20140213543-A1 NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY SLC29A1, TYMP, RNASE1 MMP9 1319/4885MMP8 2681/4885MMP1 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.